Century Therapeutics, Inc.

IPSCNASDAQHealthcare● Active

$2.12

$-0.01(-0.47%)

Market Cap$183527105

P/E Ratio—

52W High$3.04

52W Low$0.435

Avg Volume1.2M

Open$2.13

Beta1.57

Overview

Century Therapeutics, Inc. (IPSC) Insider Trading

Form 4 buy vs sell counts, ratio, and sentiment — switch this quarter or last 12 months; chart and transactions below.

SEC EDGAR · FMP · IPSC · as of Jun 9, 2026

Activity summary

Buy transactions

P-Purchase only

Sell transactions

12 Months

Buy/Sell ratio

0.21

Buy/Sell (by trades)

Overall sentiment

BEARISH

↑ Buy 18%Active transactions only · RSU vesting excluded82% Sell ↓

Century Therapeutics, Inc. insiders have been primarily selling shares over the past 12 Months. Selling activity is often driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment toward the company.

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · Buy = P-Purchase only · Sell = S-Sale only

As of Jun 9, 2026

IPSC insider buying and selling by quarter

IPSC insider selling · IPSC insider buying stocks · quarterly insider activity

Total insider buying (incl. awards)Total insider selling

2.6M1.3M0

2024 Q3

2024 Q4

2025 Q1

2025 Q2

2025 Q3

2025 Q4

2026 Q1

2026 Q2

Mobile shows last 4Q · Desktop shows full 8Q

▸ Source: SEC EDGAR · Form 3 & 4 · via Financial Modeling Prep · last 8 quarters

As of Jun 9, 2026

Active insiders

Most active in past 12 months · IPSC ceo insider trading

Showing all insiders · Click a card to filter the transactions table below

▸ Aggregated from reportingName · top 5 by trade count (12M) · no extra API

Recent insider transactions

IPSC executive sell shares · IPSC board member insider trading · IPSC insider trading SEC filing

Showing 67 most recent · Common Stock · Form 4 only

Scroll horizontally to see all columns

Date	Insider	Type	Shares	Price	Value	After trans.	Filing
May 15, 2026	Pfeiffenberger Brent President and CEO · Director	Other	31,172	$2.34	$73K	3,679,786	Form 4
May 4, 2026	Carr Douglas SVP Finance & Operations	Sale	264	$2.34	$618	506,997	Form 4
Apr 1, 2026	Cowan Chad Chief Scientific Officer	Other	1,365	$2.19	$3K	1,175,680	Form 4
Mar 12, 2026	Carr Douglas SVP Finance & Operations	Sale	7,043	$2.55	$18K	507,261	Form 4
Mar 12, 2026	Russotti Gregory See Remarks	Sale	10,076	$2.55	$26K	515,427	Form 4
Mar 11, 2026	Pfeiffenberger Brent President and CEO · Director	Other	55,397	$2.73	$151K	3,710,958	Form 4
Mar 11, 2026	Cowan Chad Chief Scientific Officer	Other	1,431	$2.73	$4K	1,177,045	Form 4
Mar 9, 2026	Russotti Gregory See Remarks	Sale	479	$2.54	$1K	525,503	Form 4
Mar 6, 2026	Pfeiffenberger Brent President and CEO · Director	Other	463	$2.56	$1K	3,766,355	Form 4
Feb 13, 2026	Pfeiffenberger Brent President and CEO · Director	Other	31,172	$1.75	$55K	3,766,818	Form 4
Feb 3, 2026	Carr Douglas SVP Finance & Operations	Sale	323	$1.82	$589	514,551	Form 4
Feb 2, 2026	Pfeiffenberger Brent President and CEO · Director	Award	475,000	—	—	3,797,990	Form 4
Feb 2, 2026	Russotti Gregory See Remarks	Award	135,000	—	—	525,982	Form 4
Feb 2, 2026	Cowan Chad Chief Scientific Officer	Award	135,000	—	—	1,178,476	Form 4
Feb 2, 2026	Carr Douglas SVP Finance & Operations	Award	110,000	—	—	514,874	Form 4
Jan 2, 2026	Cowan Chad Chief Scientific Officer	Other	1,611	$0.99	$2K	1,043,476	Form 4
Dec 22, 2025	Cowan Chad Chief Scientific Officer	Purchase	58,060	$0.85	$49K	1,045,087	Form 4
Dec 12, 2025	Pfeiffenberger Brent President and CEO · Director	Purchase	52,000	$0.58	$30K	3,322,990	Form 4
Dec 10, 2025	Pfeiffenberger Brent President and CEO · Director	Other	463	$0.53	$244	3,270,990	Form 4
Dec 8, 2025	Carr Douglas SVP Finance & Operations	Sale	257	$0.53	$137	404,874	Form 4
Dec 8, 2025	Russotti Gregory See Remarks	Sale	526	$0.53	$280	390,982	Form 4
Nov 20, 2025	Cowan Chad Chief Scientific Officer	Sale	5,462	$0.50	$3K	987,027	Form 4
Nov 19, 2025	Pfeiffenberger Brent President and CEO · Director	Purchase	35,000	$0.50	$17K	3,271,453	Form 4
Nov 17, 2025	Pfeiffenberger Brent President and CEO · Director	Sale	32,456	$0.45	$15K	3,236,453	Form 4
Nov 3, 2025	Carr Douglas SVP Finance & Operations	Sale	292	$0.59	$171	405,131	Form 4

Pfeiffenberger Brent

President and CEO · Director

Other

Date

May 15

31,172

Price

$2.34

Value

$73K

View Form 4 on SEC.gov

Carr Douglas

SVP Finance & Operations

Sale

Date

May 4

264

Price

$2.34

Value

$618

View Form 4 on SEC.gov

Cowan Chad

Chief Scientific Officer

Other

Date

Apr 1

1,365

Price

$2.19

Value

$3K

View Form 4 on SEC.gov

Carr Douglas

SVP Finance & Operations

Sale

Date

Mar 12

7,043

Price

$2.55

Value

$18K

View Form 4 on SEC.gov

Russotti Gregory

See Remarks

Sale

Date

Mar 12

10,076

Price

$2.55

Value

$26K

View Form 4 on SEC.gov

Pfeiffenberger Brent

President and CEO · Director

Other

Date

Mar 11

55,397

Price

$2.73

Value

$151K

View Form 4 on SEC.gov

Cowan Chad

Chief Scientific Officer

Other

Date

Mar 11

1,431

Price

$2.73

Value

$4K

View Form 4 on SEC.gov

Russotti Gregory

See Remarks

Sale

Date

Mar 9

479

Price

$2.54

Value

$1K

View Form 4 on SEC.gov

Pfeiffenberger Brent

President and CEO · Director

Other

Date

Mar 6

463

Price

$2.56

Value

$1K

View Form 4 on SEC.gov

Pfeiffenberger Brent

President and CEO · Director

Other

Date

Feb 13

31,172

Price

$1.75

Value

$55K

View Form 4 on SEC.gov

Carr Douglas

SVP Finance & Operations

Sale

Date

Feb 3

323

Price

$1.82

Value

$589

View Form 4 on SEC.gov

Pfeiffenberger Brent

President and CEO · Director

Award

Date

Feb 2

475,000

Price

—

Value

—

View Form 4 on SEC.gov

Russotti Gregory

See Remarks

Award

Date

Feb 2

135,000

Price

—

Value

—

View Form 4 on SEC.gov

Cowan Chad

Chief Scientific Officer

Award

Date

Feb 2

135,000

Price

—

Value

—

View Form 4 on SEC.gov

Carr Douglas

SVP Finance & Operations

Award

Date

Feb 2

110,000

Price

—

Value

—

View Form 4 on SEC.gov

Cowan Chad

Chief Scientific Officer

Other

Date

Jan 2

1,611

Price

$0.99

Value

$2K

View Form 4 on SEC.gov

Cowan Chad

Chief Scientific Officer

Purchase

Date

Dec 22

58,060

Price

$0.85

Value

$49K

View Form 4 on SEC.gov

Pfeiffenberger Brent

President and CEO · Director

Purchase

Date

Dec 12

52,000

Price

$0.58

Value

$30K

View Form 4 on SEC.gov

Pfeiffenberger Brent

President and CEO · Director

Other

Date

Dec 10

463

Price

$0.53

Value

$244

View Form 4 on SEC.gov

Carr Douglas

SVP Finance & Operations

Sale

Date

Dec 8

257

Price

$0.53

Value

$137

View Form 4 on SEC.gov

Russotti Gregory

See Remarks

Sale

Date

Dec 8

526

Price

$0.53

Value

$280

View Form 4 on SEC.gov

Cowan Chad

Chief Scientific Officer

Sale

Date

Nov 20

5,462

Price

$0.50

Value

$3K

View Form 4 on SEC.gov

Pfeiffenberger Brent

President and CEO · Director

Purchase

Date

Nov 19

35,000

Price

$0.50

Value

$17K

View Form 4 on SEC.gov

Pfeiffenberger Brent

President and CEO · Director

Sale

Date

Nov 17

32,456

Price

$0.45

Value

$15K

View Form 4 on SEC.gov

Carr Douglas

SVP Finance & Operations

Sale

Date

Nov 3

292

Price

$0.59

Value

$171

View Form 4 on SEC.gov

⚡ = value ≥ $1M · Award/Option price shows — · formType=4 · securityName=Common Stock · url → sec.gov/Archives/edgar

1 / 3

▸ Source: SEC EDGAR · Form 4 filings · ⚡ = value ≥ $1M · Award/Option price shows —

About IPSC insider trading

IPSC insider trades

Century Therapeutics, Inc. (IPSC) insider trading data is sourced from SEC Form 4 filings submitted by corporate insiders, including Pfeiffenberger Brent (President and CEO · Director), Carr Douglas (SVP Finance & Operations), Cowan Chad (Chief Scientific Officer). Over the past 12 months, 4 insiders have filed transactions with the SEC. IPSC insiders have been primarily selling, which may reflect pre-scheduled Rule 10b5-1 plan executions.

For Century Therapeutics, Inc.'s institutional ownership breakdown and insider ownership percentage, see the Ownership tab → Ownership tab →

Buy/Sell signal logic

acquisitionOrDisposition field:

A = Acquisition (buy) · D = Disposition (sell)

RSU vesting (M-Exempt) excluded from sentiment

Form 4SEC filing required within 2 business days of any insider transaction

10b5-1Pre-scheduled trading plan that allows insiders to sell on autopilot

Open MktDirect purchase or sale on the open market (excludes awards, options)

Ownership SEC filings Financial statements Price history Forecast & ratings Earnings

Frequently asked questions

IPSC insider trading · 5 questions

The insiders of Century Therapeutics, Inc. (IPSC) include executives and directors such as Pfeiffenberger Brent (President and CEO · Director), Carr Douglas (SVP Finance & Operations), Cowan Chad (Chief Scientific Officer), among others. Over the past 12 months, 4 insiders have filed Form 4 transactions with the SEC. Insider transactions are required to be reported within 2 business days of the trade date.

IPSC board member insider tradingwho are IPSC insidersIPSC insider rosterCentury Therapeutics, Inc. executives insider activity

▸ Source: FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · acquisitionOrDisposition A=Buy, D=Sell · RSU vesting (M-Exempt) excluded from sentiment bar · As of Jun 9, 2026